8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  August 7, 2014 (August 7, 2014)

CHEMBIO DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada	0-30379	88-0425691
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)
	3661 Horseblock Road
	Medford, NY 11763
	(Address of principal executive offices)
	631-924-1135
	(Registrant's Telephone Number)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01.  REGULATION FD DISCLOSURE.

On August 7, 2014, the Company issued a press release entitled "Chembio Diagnostics Reports Second Quarter 2014 Financial Results".   A copy of the press release is furnished herewith as Exhibit 99.1.

On August 7 2014, the Company posted a PowerPoint Presentation to their website entitled "Investor Presentation August 2014."  A copy of the presentation is furnished herewith as Exhibit 99.2.

In addition, also on August 7, 2014, the Company posted an Investor Fact Sheet to their website.  A copy of the fact sheet is furnished herewith as Exhibit 99.3

The information in this Item 7.01 of this Form 8-K is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Form 8-K also shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.

ITEM 9.01.FINANCIAL STATEMENTS AND EXHIBITS

Exhibits.

99.1	Press Release entitled "Chembio Diagnostics Reports Second Quarter 2014 Financial Results" dated August 7, 2014
99.2	Presentation entitled "Investor Presentation August 2014" dated August 7, 2014.
99.3	Investor Fact Sheet posted to the company website dated August 7, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

August 7, 2014          Chembio Diagnostics, Inc.

By:    /s/ John J. Sperzel III                                      

John J. Sperzel III

Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release entitled "Chembio Diagnostics Reports Second Quarter 2014 Financial Results" dated August 7, 2014
99.2	Presentation entitled "Investor Presentation August 2014" dated August 2014.
99.3	Investor Fact Sheet posted to the company website dated August 7, 2014.

EX-99.1

Chembio Diagnostics Reports Second Quarter 2014 Financial Results

Conference Call and Webcast Today at 10:00 a.m. Eastern

MEDFORD, NY, August 7, 2014 -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the second quarter ended June 30, 2014.

Financial highlights for the 2014 second quarter include the following (all comparisons are with the 2013 second quarter):

• Total revenues of $7.42 million, an increase of 37.6 % compared with $5.39 million

• Product sales of $7.25 million, an increase of 43.2% compared with $5.06 million

• Operating loss of $233,000, compared with operating loss of $380,000

• Net loss of $146,000, or $0.02 per diluted share, compared with net loss of $241,000, or $0.03 per diluted share

Financial highlights for the first six months of 2014 include the following (all comparisons are with the first six months of 2013):

• Total revenues of $13.24 million, an increase of 9.6% compared with $12.07 million

• Product sales of $12.15 million, an increase of 6.8% compared with $11.37 million

• Operating loss of $616,000, compared with operating income of $107,000

• Net loss of $371,000, or $0.04 per diluted share, compared with net income of $76,000, or $0.01 per diluted share

John J. Sperzel III, Chembio's Chief Executive Officer, stated, "As we reach the mid-point of the year, we are very pleased with our key accomplishments.  Revenue increased on a quarterly and year-to-date basis, compared to prior year periods. We successfully launched our U.S. commercial organization and expanded our production capacity.  We are optimistically awaiting the FDA response to our CLIA waiver application for the Chembio DPP® HIV 1/2 Assay, which, if positive, would unlock significant new markets for us. Our international partners continue to build demand for our products overseas. And lastly, our leadership team is actively evaluating opportunities for new product development and strategic partnerships beyond infectious disease.  We expect the Company's progress in each of these areas to sustain Chembio's growth in the future."

Second Quarter Results

Total revenues for the second quarter of 2014 of $7.42 million were up 37.6% compared with total revenues of $5.39 million in the prior-year period. Product sales in the 2014 second quarter of $7.25 million were up 43.2% compared with product sales of $5.06 million in the prior-year period.  Research and development ("R&D"), milestone, and grant and royalty revenues for the three months ended June 30, 2014 decreased to $167,000 from $332,000 in the prior-year period.

Gross margin for the 2014 second quarter increased 30.8% to $2.98 million compared with $2.28 million for the prior-year period, due primarily to higher product sales. Product gross margin for the second quarter of 2014 increased 44.1% to $2.81 million, from $1.95 million in the prior-year period, also primarily as a result of the higher product sales.

R&D expenses in the second quarter of 2014 were $1.27 million, compared with $1.50 million in the prior-year period.

Selling, general and administrative expenses in the second quarter of 2014 increased to $1.95 million from $1.16 million in the prior-year period, largely due to increased commissions and investment in sales and marketing personnel and related costs.

Operating loss for the second quarter of 2014 was $233,000, compared with operating loss of $380,000 for the prior-year period.

Net loss for the second quarter of 2014 was $146,000, or $0.02 per diluted share, compared with net loss of $241,000, or $0.03 per diluted share, for the prior-year period.

Six-Month Results

Total revenues for the first six months of 2014 of $13.24 million were up 9.6% compared with total revenues of $12.07 million in the prior-year period. Product sales in the 2014 first six months of $12.15 million were up 6.8% compared with product sales of $11.37 in the prior-year period, primarily due to increases in DPP® product sales in Brazil to FIOCRUZ.   Research and development ("R&D"), milestone, grant and royalty revenues for the six months ended June 30, 2014 increased to $1,076,000 from $697,000 in the prior-year period.

Gross margin for the 2014 first six months increased 5.6% to $5.26 million compared with $4.98 million for the prior-year period. Product gross margin for the first six months of 2014 decreased 2.5% to $4.17 million, from $4.28 million in the prior-year period.

R&D expenses in the first six months of 2014 were $2.47 million, compared with $2.55 million in the prior-year period. 

Selling, general and administrative expenses in the first six months of 2014 increased to $3.40 million from $2.32 million in the prior-year period, largely due to commissions, wages and related expenses, and other expenses.

Operating loss for the first six months of 2014 was $616,000, compared with operating income of $107,000 for the prior-year period.  

Net loss for the first six months of 2014 was $371,000, or $0.04 per diluted share, compared with net income of $76,000, or $0.01 per diluted share, for the prior-year period. 

Balance Sheet Highlights

The Company had cash and cash equivalents of $6.84 million as of June 30, 2014, compared with $9.65 million as of December 31, 2013. The primary reason for this decrease was due to net cash used in operating activities of $2.54 million for the six months of 2014, including an increase in AR of $831,000. Our working capital decreased by $535,000 during the year from $14.22 million to $13.69 million.

Conference Call

To participate on the conference call on August 7^th at 10am ET, please dial (877) 407-0778 from the U.S. or (201) 689-8565 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until August 14, 2014 at 11:59 p.m. Eastern Time by dialing (877) 660-6853 from the U.S. or (201) 612-7415 from outside the U.S. and entering conference ID #:13587650. The conference call may also be accessed via the Internet at http://www.investorcalendar.com/IC/CEPage.asp?ID=173033.  An archive of the webcast will be available for 90 days on the Company's website at www.chembio.com.

Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of Chembio's website at www.chembio.com.  To listen to the live call, please go to the website 15 minutes prior to its start to register, download, and install the necessary audio software.  A replay will be available on the website for a limited time.

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $8.0 billion point-of-care testing market. Chembio markets its HIV 1/2 STAT-PAK^® Assay to physicians and testing sites in the U.S. and through select distributor channel partners. The Company's SURE CHECK^® HIV 1/2 Assay is marketed exclusively in the U.S. as Clearview^® Complete . Chembio also markets its HIV 1/2 STAT-PAK^® and SURE CHECK^® HIV 1/2 Assays outside the U.S. through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP^®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products. Headquartered in Medford, NY, with approximately 200 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13485. Chembio Diagnostic Systems, Inc. is a wholly-owned subsidiary of Chembio Diagnostics, Inc. For more information, please visit:www.chembio.com.

Forward-Looking Statements

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements, which are estimates only, reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing and to obtain regulatory approvals in a timely manner, as well as the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

(Tables to follow)

Contacts:

Chembio Diagnostics

Susan Norcott

(631) 924-1135, ext. 125

snorcott@chembio.com

Vida Strategic Partners (investor relations)

Stephanie C. Diaz

(415) 675-7401

sdiaz@vidasp.com

Chembio Diagnostics, Inc. & Subsidiary
Summary of Consoldidated Results of Operations
(UNAUDITED)
	For the three months ended						For the six months ended
	June 30, 2014			June 30, 2013			June 30, 2014			June 30, 2013
Net product sales	$	7,248,470		$	5,061,691		$	12,152,635		$	11,374,881
License and royalty revenue		6,971			-			7,131			-
R&D, milestone and grant revenue		167,156			331,831			1,075,904			696,794
TOTAL REVENUES	$	7,422,597		$	5,393,522		$	13,235,670		$	12,071,675
GROSS MARGIN	$	2,982,551		$	2,281,175		$	5,255,162		$	4,975,065
Research and development expenses	$	1,268,653		$	1,500,645		$	2,466,275		$	2,545,904
Selling, general and administrative expenses	$	1,946,763		$	1,160,256		$	3,404,491		$	2,322,336
(LOSS) INCOME FROM OPERATIONS	$	(232,865	)	$	(379,726	)	$	(615,604	)	$	106,825
OTHER (EXPENSE) INCOME	$	(4,146	)	$	8,397		$	(2,316	)	$	9,400
Income tax (benefit) provision	$	(91,030	)	$	(130,340	)	$	(247,200	)	$	40,090
NET (LOSS) INCOME	$	(145,981	)	$	(240,989	)	$	(370,720	)	$	76,135
Basic (loss) earnings per share	$	(0.02	)	$	(0.03	)	$	(0.04	)	$	0.01
Diluted earnings (loss) per share	$	(0.02	)	$	(0.03	)	$	(0.04	)	$	0.01
Weighted average number of shares outstanding, basic		9,555,944			9,259,506			9,448,160			8,664,478
Weighted average number of shares outstanding, diluted		9,555,944			9,259,506			9,448,160			9,230,840

Chembio Diagnostics, Inc. & Subsidiary
Summary of Consolidated Balance Sheets
	June 30, 2014			December 31, 2013
	(UNAUDITED)
CURRENT ASSETS:
Cash and cash equivalents	$	6,835,057		$	9,650,275
Accounts receivable, net of allowance for doubtful accounts of $24,000 at June 30, 2014 and December 31, 2013, respectively		5,423,418			4,592,121
Inventories		4,079,206			3,188,726
Prepaid expenses and other current assets		1,144,404			1,099,379
TOTAL CURRENT ASSETS		17,482,085			18,530,501
FIXED ASSETS, net of accumulated depreciation		2,126,956			1,978,232
OTHER ASSETS		4,448,019			3,977,859
TOTAL ASSETS	$	24,057,060		$	24,486,592
CURRENT LIABILITIES:
Accounts payable and accrued liabilities	$	3,795,872		$	4,309,490
TOTAL LIABILITIES		3,795,872			4,309,490
STOCKHOLDERS' EQUITY:
Common stock - $.01 par value; 100,000,000 shares authorized, 9,611,139 and 9,324,783 shares issued and outstanding for June 30, 2014 and December 31, 2013, respectively		96,112			93,248
Additional paid-in capital		47,326,969			46,875,027
Accumulated deficit		(27,161,893	)		(26,791,173	)
TOTAL STOCKHOLDERS' EQUITY		20,261,188			20,177,102
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	24,057,060		$	24,486,592

Chembio Diagnostics, Inc. & Subsidiary
Summary of Consolidated Cash Flow
For the six months ended
(UNAUDITED)
	June 30, 2014			June 30, 2013
Net cash (used in) provided by operating activities	$	(2,535,529	)	$	802,771
Net cash used in investing activities		(516,869	)		(415,649	)
Net cash provided by (used in) financing activities		237,180			5,306,411
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	$	(2,815,218	)	$	5,693,533

EX-99.2

RAPID Tests for EARLIER Treatment

Investor Presentation August 2014

Slide 2

Forward Looking Statements

Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.  Those statements include statements regarding the intent, belief or current expectations of Chembio and its management. Such statements reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, Chembio's ability to develop, manufacture, market and finance new products and the demand for Chembio's products.  Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Other factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Slide 3

Our Vision & Mission

We are a provider of Point-of-Care diagnostic tests and solutions, helping people live longer and healthier lives.

Our Mission is to become a key provider in the market for rapid diagnostic Point of Care (POC) testing, through the development, manufacture, and commercialization of proprietary technology with superior performance and technical service.

Slide 4

Investment Summary

• Develops, Manufactures & Markets Point-of-Care Diagnostic Tests (POCTs)

‐ Global Sales – Direct and Through Partnerships

‐ $8B Total Global Market with Current Pipeline Addressing $650MM Segment

• Five Consecutive Years of Profitability & Revenue Growth

‐ 2013 Revenues and Product Gross Margin Increased by 15% and 8% respectively vs. 2012

• Patented DPP® - A Platform POCT Technology

‐ Uniquely Enables Multiplexing for Higher Value Tests & Increased Sensitivity

‐ DPP® Oral Fluid HIV Test – FDA-Approved - CLIA waiver pending

‐ DPP® HIV-Syphilis  Test- Strong outlook for ex-US sales in 2014

• Pipeline of DPP® POCT Products

‐ DPP® HCV Ab & HIV Ag-Ab Test

Slide 5

Chembio Products are well Positioned Globally for Growth in $8.0 Billion Global Market

USA

• Branded Chembio products marketed in the U.S. beginning in 2014

• SURE CHECK® lateral flow product marketed exclusively in U.S. by a distribution partner

• DPP® HIV PMA approval (Dec'12) / CLIA pending

• Funded Research Collaborations with CDC, DOD, NIH (6% FY13)

EU

• CE mark approval for SURE CHECK® (July'13)

• CE mark for STATPAK®, DPP® HIV HIV/Syphilis pending

ASIA

· Feb. 2014 License, Distribution, Tech. Transfer and Contract Manufacturing Agreements

AFRICA

• Procurements primarily funded by PEPFAR, Global Fund, and WHO

• Sales channel; NGO-direct  & through distributors (14% FY13 revenue)

• Commercial resource deployment

SOUTH/CENTRAL AMERICA

• Strong OEM Partnerships (FIOCRUZ, Labtest); Branded products sold to NGOs, private  distributors (45% FY13)

Slide 6

Chembio Invests in Next Generation Technology

Technologies to Address An Array of Diseases and Conditions

· Lateral Flow Technology

· Single Parameter Tests

· DPP® Technology Enabling Improved Sensitivity, Multiplexing

· Ongoing R&D

Slide 7

Chembio's Lateral Flow Rapid HIV Tests Marketed World-Wide

• Total $20.2MM  FY 2013

‐ 50%  Increase vs. FY2012

‐ 5-8.5% Royalties ending Feb. 2015

• In U.S. Chembio Markets HIV 1/2 STAT PAK® and an exclusive distributer Markets SURE CHECK®

‐ $8.9MM in FY 2013

‐ 14% Increase vs. FY2012

• International Market Sold Through Multiple Channels

‐ $11.8MM in FY2013

‐ 84.5% Increase vs. FY2012

See graphics

Slide 8

Chembio's Dual Path Platform (DPP®) Patented Point-of-Care Test Technology

· Proprietary Platform Technology that Uniquely Enables Multiplexing for Higher Value Tests

· Increases Sensitivity as Compared with Lateral Flow Technology

· Validated with Numerous Partners, Regulatory Agencies

· New DPP® Patents Issued in 2013

See graphics

Slide 9

Chembio's  Pipeline: $650MM Total Addressable Market

Chembio Pipeline POCT	Total Estimated Market Opportunity	Targeted Launch
HIV POCT – U.S.	$75 MM	$8.9MM Product Sales 2013 ; New Oral Fluid Product Launch 2014
HIV-Syphilis - U.S	$75 MM	2015
Hepatitis C POCT – U.S.	$100 MM	2016
Combined Estimated Market for Above Products– ex-U.S.	$400 MM	$27.5MM  Product Sales in FY2013 Significant Growth Opportunities with Current and New Products
TOTAL:	$650MM

Slide 10

Chembio POCT Market  Opportunities: HIV Rapid POCTS

Established, Growing Markets

U.S.

• ~50,000 New Infections in 2012

• USPSTF Recommends Routine Testing

‐ ACA Expanding Coverage by 25MM+

International

• 2.5 MM New Infections Worldwide in 2012

• Designation in PEPFAR & Other Donor-Funded Countries' Testing Protocols

See graphic

Slide 11

Chembio DPP® HIV 1/2 Assay FDA-Approved Dec. '12 CLIA Waiver Application Filed with FDA, November 2013,   Anticipated Launch in 2^nd half of 2014

· Build on Established  Position/Performance  of Our FDA Lateral  Flow Products with Only Alternative to Current  ~$35MM Oral Fluid Product

· Superior Blood Matrix Performance over Top 4 Market Share Products in Early Detection Study

· Superior Oral Fluid Sensitivity v. Market Leader in Only Head-to-Head Study

· User Friendly, Safe and Efficient SampleTainer™ Sample Collection System

· Separate and Reagent-Free Oral Fluid Collection Device

See graphics

Slide 12

DPP® HIV-Syphilis Multiplex Assay

‐ Large Global Market Opportunities for Pre-Natal and MSM Screening

‐ Higher Prevalence of  Syphilis (1.9MM) than HIV (1.5MM) in Pregnant Women

‐ International & US Regulatory Approval Applications and Commercialization Efforts Underway

‐ Up to 70% HIV-Syphilis Co-Infection in MSM

• First Such Test to be USAID-approved

• Strong Start and Outlook  2014

Slide 13

OEM & License Agreements Expanding Relationships and Sales Opportunities

Oswaldo Cruz Foundation

• Five DPP® Products , ~$6MM 2013 revenues

• Brazilian MOH Supplier

Collaboration with LabTest Brazil

• Assembly & Distribution - DPP® Co-branded

• 2014 Plan = Initial Products Registrations

Agreement with RVR Malaysia

• License, Distribution, Tech. Transfer and Contract Manufacturing

 Bio-Rad Laboratories

• Exclusive Licensee for DPP® HIV Confirmatory Application

• CE Marked 2013, FDA Pending

Slide 14

Commercial Strategy: Top Line Growth (Sales)

Build a Sales & Marketing Organization to Increase Our Revenue and Maximize Profits

Tactic #1:   Move up Value Stream in US Diagnostics Market "USA Direct" for Certain Products

Tactic #2:   Future Growth – New Markets and New Applications

Tactic #3:   Maximize Opportunities in Developing World Markets

Slide 15

Additional Priorities & Areas of Focus:  Technology

Technology  Investment

• New Product Launch (DPP® HIV/SYP)

• Develop New Technologies (HIV 4G, HCV) that Address Healthcare Concerns

• Identify Additional Technologies to License/Acquire that will Complement our Commercial Strategy

See graphics

Slide 16

Organization & Facility

• FDA- and USDA-Approved Development & Manufacturing Facility in 39,660 Sq. Ft. Leased Facility in Medford, NY

• Company Warehouse in 21,450 Sq. Ft. Leased Facility in Holbrook, NY

TOTAL EMPLOYMENT: Approximately 175

Operations= 112 Employees

QA/QC = 15 Employees

R&D = 26 Employees

SG&A = 18 Employees

See graphics

Slide 17

Selected Financial Data FY2009 –2013

2013

Total Revenue $29,550

Product Revenue$ 27,516

Gross Profit $12,300

R&D Expense* $5,834

Pre-Tax Income $530,800

Clinical Trial Expense $1,515

*Non-recurring 2010 $1.5MM R&D Credit from the Affordable Care Act – excluded from 2010 R&D Exp. & 2010 Pre-Tax Income

See graphics

Slide 18

SIX MONTHS 2014 -2013- Selected Financial Highlights

Six Months Ended (in 000's)	June 30, 2014					June 30, 2013
Net Product Revenues	$	12,153				$	11,375
TOTAL REVENUES		13,236					12,072
GROSS MARGIN		5,255		40	%		4,975	41	%
INCOME FROM OPERATIONS		(616	)				107
NET INCOME	$	(371	)	-3	%	$	76	1	%
CASH AS OF	$	6,835				$	9,650

Slide 19

2013 – 2014 YTD Milestones Achieved

Product Development/Regulatory

• Received FDA PMA Approval of DPP Oral Fluid HIV Test

• Substantial Progress on CLIA waiver studies

• Received CE Mark for Sure Check HIV 1/2 Assay

• USAID Approval, Initial Sales of HV-Syphilis Test

Corporate/Operations

• Achieved  Fifth Straight Year of Sales Growth and Profitability with Strong Gains in Domestic and International Segments

• Strengthened Balance Sheet with Common Stock Issuance, Establishing Institutional Shareholder Base

• Increased Production Capacity to Meet Sales Growth

Commercialization

• Entered International Assembly & Distribution Agreement w/Labtest of Brazil

• Established Distribution, License , Tech. Transfer, Contract Manufacturer in Asia

• Initial International Registrations for HIV-Syphilis ; Receiving Significant Initial Orders

Slide 20

Anticipated Milestones - 2014

Product Development/Regulatory

• Oral Fluid HIV Test CLIA Waiver & Launch

• CE Marks for HIV 1/2 STAT-PAK®,  DPP® HIV & HIV-Syphilis Products

• International Sales Growth of DPP ® HIV-Syphilis Test

Corporate/Operations

• Increase Production Capacity

• Pursue Acquisitions or Licenses of Complementary Products/Technologies

Commercialization

• Implement US & International Commercial Strategy, Expand Market and Sales Opportunities

• Expand International Revenues for Lateral Flow and DPP® Products

• New Distribution, Contract Development & OEM Deals

Slide 21

Leadership Executive Team

Executive:  John J. Sperzel III,   Chief Executive Officer

Previous Experience: 2011-2013, President and CEO of ITC.; 1987-2011 Axis-Shield, Bayer Diagnostics, Instrumentation Laboratory and Boehringer Mannheim

Joined:  2014

Executive:  Richard Larkin, CPA  Chief Financial Officer

Previous Experience: 2000-2003  CFO of Visual Technology Group; 1987-2000 CFO of Protex  International Corp.

Joined:  2003

Executive:  Sharon Klugewicz, M.S.  Chief Operating Officer

Previous Experience: 20+ Years at Pall Corporation, most recently as Sr. VP - Scientific & Laboratory Services

Joined:  2012

Executive:  Javan Esfandiari, M.S.  Chief Science and Technology Officer

Previous Experience: 1993-1997, R&D Director On-Site Biotech;

1997-2000, Co-Founder of Sinovus Biotech AB (Sweden), which was acquired by Chembio in 2000

Joined:  2000

Executive:  Thomas Ippolito, VP Regulatory & Clinical Affairs

Previous Experience: 25 years experience in the development of vaccines, therapeutics and IVDs working with several major pharmaceutical, vaccine and diagnostic companies

Joined:  2005

Executive:  Michael Steele, VP Sales, Marketing and Business Development

Previous Experience: 20 years of business development and strategy execution at life sciences companies Sera Care Life Sciences, Serologicals, Inc. and Corautus Genetics.

Joined:  2012

Slide 22

Investment Summary

• Develops, Manufactures & Markets Point-of-Care Diagnostic Tests (POCTs)

‐ Global Sales – Direct and Through Partnerships

‐ $8B Global Market with Current Pipeline Addressing $650MM Segment

• Five Consecutive Years of Profitability & Revenue Growth

‐ 2013 Revenues and Product Gross Margin Increased by 15% and 8% respectively vs. 2012

• Patented DPP® - A Platform POCT Technology

‐ Uniquely Enables Multiplexing for Higher Value Tests & Increased Sensitivity

‐ DPP® Oral Fluid HIV Test – FDA-Approved - CLIA waiver pending

‐ DPP® HIV-Syphilis  Test- Strong outlook for international sales in 2014

• Pipeline  of DPP® POCT Products

‐ DPP® HCV Ab & HIV Ag-Ab Test

EX-99.3

PAGE 1

Investor Fact Sheet

Ticker Symbol: NASDAQ: CEMI

www.chembio.com

Business Summary & Investment Highlights

Chembio Diagnostics, Inc., (Chembio),through its wholly-owned subsidiary Chembio Diagnostic Systems, Inc. develops, manufactures, licenses and markets point-of-care testing (POCT) products.  Chembio created and patented a new revolutionary technology called Dual Path Platform (DPP®). The technology is addressing critical market requirements in the infectious diseases testing market and other growing markets. Products under development, both OEM and branded, are anticipated to create significant new revenue streams that will add to Chembio's core business of rapid HIV tests.

· Ten Consecutive Years of Double Digit Revenue Growth and Five Consecutive Years of Profitability.

· Strategy is to create core business of public health products to be complemented by OEM and selected out-licensing opportunities.

· Robust pipeline of POCT products for infectious diseases based on Chembio's patented DPP® technology.

· Products developed on DPP® platform include oral fluid HIV test approved by FDA in December 2012.   Several other products and collaborations in pipeline.

· Commercial Activities in North America, South America, Europe, Africa and Asia Ongoing to Address Growing Global Market for POCTs

Selected Financial Information

Stock Information  as of 7/31/14

Ticker Symbol: NASDAQ: CEMI

Price 07/31/2014:   $3.33

52 Week High:   $5.00

52 Week Low: $2.83

Outstanding Shares (MM): 9.61

Market Capitalization (MM): $32.10

Fully Diluted (FD) Shares (MM): 10.28

Management Holding-FD (MM):0.97

Average Daily Vol. (3 Mos):  20,000

5% Beneficial Holders Beneficial Shares Owned (000)s

Wellington Management Company, LLP: 958 

Lawrence Siebert: 840

See Graphics

Balance Sheet Data ($000s)	June '14		Dec '13
Cash	$	6,835	$	9,650
Accts. Receivable		5,423		4,592
Inventories		4,079		3,189
Total Current Assets		17,481		17,431
Net Fixed Assets		2,127		1,978
Total Assets		24,057		19,409
Total Current Liab.		3,796		4,309
Total Other Liab.		-		-
Total Liabilities		3,796		4,309
Shareholders Equity		20,261		20,177
Total Liabilities & Shareholders Equity	$	24,057	$	24,486

Selected Comparative Historical Financial Data

Quarter/Year Ended			For the Quarter Ended						For the Six Months Ended						For the Years Ended
$	(000s	)	Q2'14			Q2'13			Q2'14			Q2'13				2013			2012			2011			2010
Total Revenues			$	7,423		$	5,394			13,236			12,072		$	29,550		$	25,611		$	19,388		$	16,705
Cost of sales				4,440			3,112			7,981			7,097			17,249			14,821			9,998			8,604
Gross Profit				2,983			2,282			5,255			4,975			12,301			10,790			9,390			8,101
				40.2	%		42.3	%		39.7	%		41.2	%		41.6	%		42.1	%		48.4	%		48.5	%
R&D Expense				1,269			1,501			2,466			2,546			5,834			4,486			4,878			2,586
SG&A Expense				1,947			1,160			3,404			2,322			5,461			4,852			3,424			2,941
Operating Income (Loss)				(233	)		(379	)		(615	)		107			1,006			1,452			1,088			2,574
Other Inc. (Expense)				(4	)		8			(2	)		9			13			(1	)		(12	)		(15	)
Net Income (Loss)				(237	)		(371	)		(617	)		116			1,019			1,451			1,076			2,559
Inc Tax (Ben.) Prov.				(91	)		(130	)		(247	)		40			487			509			(5,133	)		-
Net Income (Loss)			$	(146	)	$	(241	)		(370	)		76		$	532		$	942		$	6,209		$	2,559
Net Income (Loss) - per Share				(0.02	)		(0.03	)		(0.04	)		0.01		$	0.06		$	0.11		$	0.73		$	0.29
Wt. Avg. No. Shares (Millions)				9.556			9.260			9.448			8.664			9.520			8.615			8.556			8.865
Working capital			$	13,686		$	13,189			13,686			13,189			14,221			7,630			6,134			4,560
Total assets				24,057			23,542			24,057			23,542			24,487			17,335			15,486			9,086
Total liabilities				3,796			3,929			3,796			3,929			4,310			3,460			2,991			3,277
Shareholders Equity				20,261			19,613			20,261			19,613			20,177			13,875			12,495			5,809

Chembio Diagnostics, Inc.	Investor Relations	Company Contact
3661 Horseblock Road	Vida Strategic Partners	Susan Norcott
Medford, NY 11763	Stephanie C. Diaz	631-924-1135 x125
Ph. 631-924-1135	(415) 675-7401	snorcott@chembio.com
Fax 631-924-2065	sdiaz@vidasp.com
www.chembio.com

PAGE 2 – See Graphics

DPP® Technology

Competitive Advantages For POC Testing

• Improved Sensitivity- enabled by more efficient binding method

• Easier Multiplexing- due to even and direct distribution of sample to multiple test lines

• Enhanced Sample Control- as result of independent sample migration path

• Clearer Results - efficient binding allows for improved functionality of instruments for reading and reporting of qualitative or quantitative results

Senior Management Team

John J. Sperzel, President & CEO: 25+ years of leadership in the POC Diagnostics market

Richard J. Larkin, CFO: 25+ years of leadership in Finance and Administration

Sharon Klugewicz, COO: 20+ years of leadership in Operations, Marketing, QA/RA

Javan Esfandiari, CSTO: 15+ years developing POC IVD tests and inventor of DPP®  technology

Michael Steele, VP Sales/Marketing/BD: 20+ years of commercial operations and BD IVD market

Tom Ippolito, VP RA: 20+ years of Quality and Regulatory Affairs leadership in IVD and Pharma

Independent Directors

Katherine Davis (Chairman) - Former Lieutenant Governor for the State of Indiana

Barbara DeBuono, MD, MPH: former NY Commissioner of Health and RI Director of Health

Peter Kissinger, Ph.D.: founder of a number of biotechnology / biomedical companies

Gary Meller, MD, MBA: broad experience in medical and information technology

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements, the accuracy of which is subject to risks and uncertainties. Please refer to Chembio Diagnostic's Inc. most recent Form 10-K and Forms 10-Q for additional information about the Company and related risks. –August 2014